Takeda Pharmaceutical Company Limited (TKDA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Takeda Pharmaceutical Company Limited (TKDA) has a cash flow conversion efficiency ratio of 0.049x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€373.25 Billion ≈ $436.37 Billion USD) by net assets (€7.64 Trillion ≈ $8.94 Trillion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Takeda Pharmaceutical Company Limited (TKDA) net asset quality to measure how much of total assets are equity-financed.
Takeda Pharmaceutical Company Limited - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Takeda Pharmaceutical Company Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Takeda Pharmaceutical Company Limited to evaluate the quality of earnings relative to operating cash generation.
Takeda Pharmaceutical Company Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Takeda Pharmaceutical Company Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanghai Pudong Development Bank Co Ltd
SHG:600000
|
0.109x |
|
Coca-Cola European Partners PLC
NASDAQ:CCEP
|
0.116x |
|
Samsung Biologics Co Ltd
KO:207940
|
0.051x |
|
Banco Bradesco DRC
BA:BBD
|
0.005x |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
0.171x |
|
Ambev S.A.
F:AMNA
|
0.149x |
|
Yageo Corp
TW:2327
|
0.053x |
|
STANDARD CHART.UNSP.ADR/2
F:STD0
|
N/A |
Annual Cash Flow Conversion Efficiency for Takeda Pharmaceutical Company Limited (2017–2025)
The table below shows the annual cash flow conversion efficiency of Takeda Pharmaceutical Company Limited from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see Takeda Pharmaceutical Company Limited stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | €6.94 Trillion ≈ $8.11 Trillion |
€1.06 Trillion ≈ $1.24 Trillion |
0.152x | +54.77% |
| 2024-03-31 | €7.27 Trillion ≈ $8.50 Trillion |
€716.34 Billion ≈ $837.48 Billion |
0.098x | -35.96% |
| 2023-03-31 | €6.35 Trillion ≈ $7.43 Trillion |
€977.16 Billion ≈ $1.14 Trillion |
0.154x | -22.18% |
| 2022-03-31 | €5.68 Trillion ≈ $6.64 Trillion |
€1.12 Trillion ≈ $1.31 Trillion |
0.198x | +1.20% |
| 2021-03-31 | €5.18 Trillion ≈ $6.05 Trillion |
€1.01 Trillion ≈ $1.18 Trillion |
0.195x | +37.83% |
| 2020-03-31 | €4.73 Trillion ≈ $5.53 Trillion |
€669.75 Billion ≈ $783.01 Billion |
0.142x | +122.70% |
| 2019-03-31 | €5.16 Trillion ≈ $6.04 Trillion |
€328.48 Billion ≈ $384.03 Billion |
0.064x | -66.04% |
| 2018-03-31 | €2.02 Trillion ≈ $2.36 Trillion |
€377.85 Billion ≈ $441.75 Billion |
0.187x | +39.67% |
| 2017-03-31 | €1.95 Trillion ≈ $2.28 Trillion |
€261.36 Billion ≈ $305.56 Billion |
0.134x | -- |
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Take… Read more